|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 29th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceuticals
|
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
105.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 29th, 2022 11:33AM
|
Aug 29th, 2022 11:33AM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 28th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
104.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 28th, 2022 04:32AM
|
Aug 28th, 2022 04:32AM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 27th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative to address the deeply interrelated issues of climate, health, and equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil fuels across the company’s operations, build collaborations with renowned institutions to advance the science to improve human health outcomes, and support underserved communities.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
104.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 27th, 2022 03:52AM
|
Aug 27th, 2022 03:52AM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 25th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
104.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 25th, 2022 08:31AM
|
Aug 25th, 2022 08:31AM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 23rd, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
104.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 23rd, 2022 10:25AM
|
Aug 23rd, 2022 10:25AM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 21st, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
103.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 21st, 2022 12:08PM
|
Aug 21st, 2022 12:08PM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 20th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
103.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 20th, 2022 01:45PM
|
Aug 20th, 2022 01:45PM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 19th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
100.00
|
About two weeks
|
103.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 19th, 2022 12:08PM
|
Aug 19th, 2022 12:08PM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 18th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
99.00
|
About two weeks
|
102.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 18th, 2022 03:52AM
|
Aug 18th, 2022 03:52AM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:biib
|
https://www.indeed.com/cmp/biogen
|
Aug 17th, 2022 12:00AM
|
Open
|
Biogen
|
|
Pharmaceutical & Biotechnology
|
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics.
With more than 7,000 people worldwide, Biogen is truly a global organization. We are headquartered in Cambridge, Massachusetts, which is home to our research operations. Our international operations are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. With a strong affiliate presence and a network of distribution partners, Biogen has established a global footprint that allows us to capture the greatest value for the products we develop.
All qualified applicants will receive consideration for employment without regard to sex, gender identity or expression, sexual orientation, marital status, race, color, national origin, ancestry, ethnicity, religion, age, veteran status, disability, genetic information or any other basis protected by federal, state or local law. Biogen is an E-Verify Employer in the United States.
|
RRv1_OVER_10B
|
Cambridge, Massachusetts
|
Michel Vounatsos
|
|
|
4.00
|
76.0
|
74.0
|
71.0
|
79.0
|
69.0
|
69.0
|
66.0
|
74.0
|
64.0
|
70.0
|
69.0
|
74.0
|
76.0
|
115.0
|
501.00
|
501.00
|
3.80
|
4.30
|
3.30
|
3.40
|
3.90
|
99.00
|
About two weeks
|
102.00
|
MEDIUM
|
100.00
|
FAVORABLE
|
|
|
|
Aug 17th, 2022 09:31AM
|
Aug 17th, 2022 09:31AM
|
Biogen
|
Health Care
|
Pharmaceuticals & Biotechnology
|